Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat

Transplantation

Volumn 62, Issue 6, 1996, Pages 861-863

  Yeh, Lih Seng ^a   Gregory, Clare R ^a   Griffey, Stephen M ^a   Lecouteur, Richard A ^a   Morris, Randall E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; LEFLUNOMIDE;

ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN GRAFT; SURVIVAL RATE;

EID: 0029780315     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609270-00027     Document Type: Article

References (10)

1. Dorrler J, Goring H, Gossmann R, et al. Limb allograft survival under cyclosporine treatment. Transplant Proc 1986; 18: 1431.
2. Lee WPA, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87: 401.
3. Cao WW, Kao PN, Chao AC, et al. Mechanism of the antiproliferative action of leflunomide. J Heart Lung Transplant (in press).
4. Morris RE, Huang X, Cao WW, et al. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 1995; 27: 445.
5. Kuchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083.
6. Yuh D, Morris RE, Hoyt G, et al. Leflunomide prolongs pulmonary allograft and xenograft survival. J Heart Lung Transplant (in press).
7. Morris RE, Huang XF, Shorthouse R et al. Use of cyclosporine (CsA), mycophenolic acid (MPA), rapamycin (RPM), leflunomide (LFM) or deoxyspergualin (DSG) for prevention and treatment of obliterative airway disease (OAD) in new animal models (abstract). J Heart Lung Transplant 1995; 14: S65.
8. Lirtzman RL, Gregory CR, Griffey SM, et al. Combination leflunomide and cyclosporine immunosuppression prevents MLR mismatched allograft rejection in mongrel dogs. Transplant Proc (in press).
9. Yeh LS, Hou SM, Lin AC, Lin J. A modified free gracilis flap in the rat. Microsurgery 1994; 15: 322.
10. Stites DP, Channing RP. Clinical laboratory methods for detection of antigens and antibodies. In: Sites DP, Stobo JD, Wells JV, eds. Basic and clinical immunology. Los Altos, CA: Appleton and Lange, 1987: 241.